Ali Ünal

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Michel Attal, Paul G. Richardson, S. Vincent Rajkumar et al. · The Lancet · 2019 · 636 citations

Medicine, Hematology, Pharmacotherapy +15

A randomized clinical trial of combination chemotherapy with and without low‐molecular‐weight heparin in small cell lung cancer

H.Ş. Çoşkun, Özlem Er, Metin Özkan et al. · Journal of Thrombosis and Haemostasis · 2004 · 456 citations

Medicine, Oncology, Pharmacology +10

Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

Meletios Α. Dimopoulos, Evangelos Terpos, Mario Boccadoro et al. · The Lancet Oncology · 2021 · 327 citations

Medicine, Hematology, Oncology +14

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

Meletios Α. Dimopoulos, Francesca Gay, Fredrik Schjesvold et al. · The Lancet · 2018 · 236 citations · Full text

Medicine, Hematology, Pharmacotherapy +15

Current outcome of HLA identical sibling versus unrelated donor transplants in severe aplastic anemia: an EBMT analysis

Almalina Bacigalupo, Gèrard Socié, Rose Marie Hamladji et al. · Haematologica · 2015 · 180 citations · Full text

Medicine, Hematology, Immunology +17